Adult CIRB - Late Phase Emphasis Meeting Agenda

July 2, 2020

I Continuing Review

A091404, A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers (Protocol Version Date 09/10/19)

II Continuing Review

EA6174, STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial (Protocol Version Date 03/05/20)

III Continuing Review

NRG-GY021, A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer (Protocol Version Date 04/24/20)

IV Continuing Review

S1500, A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) (Protocol Version Date 06/01/20)

V New Study - Initial Review

EA2176, A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients (Protocol Version Date 05/28/20)
VI New Study - Initial Review

**EA6191**, The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma (Protocol Version Date 06/08/20)

VII New Study - Initial Review

**S1931**, Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) (Protocol Version Date 06/01/20)

VIII Amendment

**A021602**, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) (Protocol Version Date 06/05/20)

IX Amendment

**RTOG-1216**, Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, Squamous Cell Cancer of the Head and Neck (Protocol Version Date 06/05/20)